Inhibitory roles of miR-320 in osteosarcoma via regulating E2F1

Journal of Cancer Research and Therapeutics

Volumn 12, Issue 5, 2016, Pages C68-C71

  Wu, Haojie ^a   Li, Weihua ^a   Zhang, Minghui ^a   Zhu, Shutao ^a   Zhang, Dengfeng ^a   Wang, Xiao ^a  

^a HENAN UNIVERSITY   (China)

Author keywords

Cell cycle; E2F1; miR 320; osteosarcoma; proliferation

Indexed keywords

MESSENGER RNA; MICRORNA; MICRORNA 320; PROTEIN; TRANSCRIPTION FACTOR E2F1; UNCLASSIFIED DRUG; 3' UNTRANSLATED REGION; MIRN320 MICRORNA, HUMAN;

3' UNTRANSLATED REGION; ARTICLE; BIOINFORMATICS; CELL CYCLE ARREST; CELL CYCLE REGULATION; CELL PROLIFERATION; CONTROLLED STUDY; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENE FUNCTION; HUMAN; HUMAN CELL; LUCIFERASE ASSAY; MTT ASSAY; NORMAL HUMAN; OSTEOBLAST; OSTEOSARCOMA; OSTEOSARCOMA CELL LINE; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSCRIPTION REGULATION; U2OS CELL LINE; WESTERN BLOTTING; BINDING SITE; CELL CYCLE CHECKPOINT; DISEASE COURSE; GENETICS; METABOLISM; NUCLEOTIDE SEQUENCE; PATHOLOGY; RNA INTERFERENCE; TUMOR CELL LINE;

3' UNTRANSLATED REGIONS; BASE SEQUENCE; BINDING SITES; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE PROGRESSION; E2F1 TRANSCRIPTION FACTOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; OSTEOSARCOMA; RNA INTERFERENCE;

EID: 84993949938     PISSN: 09731482     EISSN: 19984138     Source Type: Journal    
DOI: 10.4103/0973-1482.191635     Document Type: Article

References (17)

1. Ando K, Heymann MF, Stresing V, Mori K, Rédini F, Heymann D. Current therapeutic strategies and novel approaches in osteosarcoma. Cancers (Basel) 2013;5:591-616.
2. Clark JC, Dass CR, Choong PF. A review of clinical and molecular prognostic factors in osteosarcoma. J Cancer Res Clin Oncol 2008;134:281-97.
3. Mirabello L, Troisi RJ, Savage SA. Osteosarcoma incidence and survival rates from 1973 to 2004: Data from the surveillance, epidemiology, and end results program. Cancer 2009;115:1531-43.
4. Qureshi A, Ahmad Z, Azam M, Idrees R. Epidemiological data for common bone sarcomas. Asian Pac J Cancer Prev 2010;11:393-5.
5. Meyers PA, Schwartz CL, Krailo MD, Healey JH, Bernstein ML, Betcher D, et al. Osteosarcoma: The addition of muramyl tripeptide to chemotherapy improves overall survival-A report from the Children's Oncology Group. J Clin Oncol 2008;26:633-8.
6. Sun K, Lai EC. Adult specific functions of animal microRNAs. Nat Rev Genet 2013;14:535-48.
7. Esteller M. Non coding RNAs in human disease. Nat Rev Genet 2011;12:861-74.
8. Chou J, Shahi P, Werb Z. microRNA mediated regulation of the tumor microenvironment. Cell Cycle 2013;12:3262-71.
9. Sampson VB, Yoo S, Kumar A, Vetter NS, Kolb EA. MicroRNAs and potential targets in osteosarcoma: Review. Front Pediatr 2015;3:69.
10. Kafchinski LA, Jones KB. MicroRNAs in osteosarcomagenesis. Adv Exp Med Biol 2014;804:119-27.
11. Schaar DG, Medina DJ, Moore DF, Strair RK, Ting Y. miR 320 targets transferrin receptor 1 (CD71) and inhibits cell proliferation. Exp Hematol 2009;37:245-55.
12. Bronisz A, Godlewski J, Wallace JA, Merchant AS, Nowicki MO, Mathsyaraja H, et al. Reprogramming of the tumour microenvironment by stromal PTEN regulated miR 320. Nat Cell Biol 2011;14:159-67.
13. Khew Goodall Y, Goodall GJ. Stromal miR 320 keeps an oncogenic secretome in check. Nat Cell Biol 2012;14:124-5.
14. Cheng C, Chen ZQ, Shi XT. MicroRNA 320 inhibits osteosarcoma cells proliferation by directly targeting fatty acid synthase. Tumour Biol 2014;35:4177-83.
15. Siclari VA, Qin L. Targeting the osteosarcoma cancer stem cell. J Orthop Surg Res 2010;5:78.
16. Yin M, Wang X, Yao G, Lü M, Liang M, Sun Y, et al. Transactivation of micrornA 320 by microRNA 383 regulates granulosa cell functions by targeting E2F1 and SF 1 proteins. J Biol Chem 2014;289:18239-57.
17. Sun JY, Xiao WZ, Wang F, Wang YQ, Zhu YH, Wu YF, et al. MicroRNA 320 inhibits cell proliferation in glioma by targeting E2F1. Mol Med Rep 2015;12:2355-9.